Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nucl Med Biol ; 41(6): 477-87, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24768145

RESUMO

INTRODUCTION: The urokinase plasminogen activator (uPA) system is a proteolytic cascade involved in tumor invasion and metastasis. uPA and its inhibitor PAI-1 are described as biomarkers for breast cancer with the highest level of evidence. The present study describes the synthesis and first in vivo application of an activity based uPA PET probe. METHODS: Based on the design of a small irreversible and selective uPA inhibitor we developed an (18)F-labeled activity based probe for uPA imaging. Human uPA expressing MDA-MB-231-luc2-GFP cells were inoculated in the mammary fat pads of nude mice and treated with the probe once tumors reached a volume of 150mm(3). Scans were performed at 0.25, 0.75, 1.5, 4 and 6h post injection. To evaluate tumor uptake in vivo and ex vivo data were gathered. Biodistribution data of the organs and tissues of interest were collected at all time points. Due to a relatively low tumor uptake, probe stability was further evaluated. RESULTS: The uPA targeting PET tracer was produced in high purity and with good specific radioactivity. In vivo PET data showed a maximum tumor uptake of 2,51±0,32 %ID/g at 4h p.i. A significant correlation between in vivo and ex vivo tumor uptake calculation was found (R=0.75; p<0.01). Due to a high blood signal at all time points, probe stability was further examined revealing high plasma protein binding and low plasma stability. CONCLUSIONS: In vivo and ex vivo results clearly demonstrate that uPA expressing tumors can be detected with non-invasive PET imaging. Stability tests suggest that further optimization is needed to provide a better tumor-to-background contrast.


Assuntos
Radioisótopos de Flúor , Tomografia por Emissão de Pósitrons/métodos , Inibidores de Proteases/síntese química , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidores , Animais , Linhagem Celular Tumoral , Técnicas de Química Sintética , Estabilidade de Medicamentos , Regulação Neoplásica da Expressão Gênica , Humanos , Marcação por Isótopo , Camundongos , Inibidores de Proteases/farmacocinética , Inibidores de Proteases/farmacologia , Distribuição Tecidual , Ativador de Plasminogênio Tipo Uroquinase/metabolismo
2.
Bioorg Med Chem Lett ; 22(23): 7174-8, 2012 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-23084903

RESUMO

This letter reports the synthesis and structure-activity relationship (SAR) study of a series of triazine dimers as novel antiviral agents. These compounds were obtained through a bivalent ligand approach in which two triazine moieties are covalently connected by suitable linkers. Several compounds showed submicromolar activity against wild-type HIV-1 and moderate activity against single mutant strains.


Assuntos
Inibidores da Transcriptase Reversa/química , Inibidores da Transcriptase Reversa/síntese química , Triazinas/química , Linhagem Celular , Dimerização , Transcriptase Reversa do HIV/antagonistas & inibidores , Transcriptase Reversa do HIV/metabolismo , HIV-1/efeitos dos fármacos , HIV-1/enzimologia , Humanos , Inibidores da Transcriptase Reversa/farmacologia , Relação Estrutura-Atividade , Triazinas/síntese química , Triazinas/farmacologia
3.
Bioorg Med Chem ; 20(4): 1557-68, 2012 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-22285569

RESUMO

Recent drug discovery programs targeting urokinase plasminogen activator (uPA) have resulted in nonpeptidic inhibitors consisting of amidine or guanidine functional groups attached to aromatic or heteroaromatic scaffolds. There is a general problem of poor oral bioavailability of these charged inhibitors. In this paper, we report the synthesis and evaluation of a series of naphthamide and naphthalene sulfonamides as uPA inhibitors containing non-basic groups as substitute for amidine or guanidine groups.


Assuntos
Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidores , Amidas/síntese química , Amidas/química , Amidas/farmacologia , Ligação Competitiva , Disponibilidade Biológica , Inibidores Enzimáticos/química , Concentração de Íons de Hidrogênio , Concentração Inibidora 50 , Estrutura Molecular , Naftalenos/síntese química , Naftalenos/química , Naftalenos/farmacologia , Ligação Proteica/efeitos dos fármacos , Sulfonamidas/síntese química , Sulfonamidas/química , Sulfonamidas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA